Alkem Laboratories Ltd. · NSE:ALKEM
Alkem Laboratories — Q4 FY16 Earnings Presentation
14 slides from Alkem Laboratories's earnings presentation, May 27, 2016
Slide 1: Alkem Laboratories Limited Investor Presentation Q4FY16
Alkem Laboratories Limited Investor Presentation Q4FY16 27th May 2016
Slide 2: Safe Harbor Statement
Safe Harbor Statement This presentation contains forward-looking statements and information that involve risks, uncertainties and assumptions. Forward-looking statements are all statements that concern plans, objectives, goals, strategies, future events or performance and underlying assumptions and
Slide 3: FY16 – A Satisfying Year For The Company
FY16 – A Satisfying Year For The Company • Successful IPO Listing – The Company got listed on the NSE and the BSE in December 2015 with its IPO book getting subscribed over 40 times • Profitable Growth - Net operating income during the year grew by 33.3%* with more than 500bps year-on-year improveme
Slide 4: Financial Highlights – Q4FY16 Consolidated
Financial Highlights – Q4FY16 Consolidated All figures in INR mn Net Income from Operations Net Sales – Geographical Split Domestic International 25.3% 22.8% 28.1% 11,426 7,748 3,361 9,119 6,309 2,624 Q4FY15 Q4FY16 Q4FY15 Q4FY16 Q4FY15 Q4FY16 EBITDA PBT 17.4% 9.0% 1,639 1,580 1,504 1,346 14.8% 13.8%
Slide 5: Financial Highlights – FY16 Consolidated
Financial Highlights – FY16 Consolidated All figures in INR mn Net Income from Operations Net Sales – Geographical Split Domestic International 33.3% 30.4% 41.3% 49,915 35,362 13,407 37,434 27,127 9,489 FY15 FY16 FY15 FY16 FY15 FY16 EBITDA PBT 101% 87.5% 8,482 8,451 4,218 4,508 11.3% 17.0% 12.0% 16.
Slide 6: Business Highlight Q4FY16 – India Business
Business Highlight Q4FY16 India Business: Q4FY16 Net Sales of Rs.7,748 million (22.8% growth1 YoY) India sales INRmn • India sales contributed 69.7% to total net sales 7,748 35,362 for Q4FY16 6,309 27,127 • During the quarter and the year, our secondary sales2 grew by 13.2% and 14.4% respectively –
Slide 7: Business Highlight Q4FY16 – India Therapy Performance
Business Highlight Q4FY16 India Business: Therapy Performance during Q4FY16 Established therapeutic areas of Alkem Market rank 1 3 3 +1 5 +2 Market share4 11.4% 6.0% 5.0% 3.7% 20.6% 17.4% 15.9% 12.5% 12.2% 9.4% 8.0% 4.9% Anti-infectives Gastro-intestinal Pain/ Analgesics Vitamins/ Minerals / Nutrien
Slide 8: Business Highlight Q4FY16 – US Business
Business Highlight Q4FY16 US Business: Q4FY16 Net Sales of Rs.2,434 million (17.9% growth YoY) • US sales contributed 21.9% to total net sales for Q4FY16 US sales INRmn • Filed 6 ANDAs during the quarter, taking the cumulative ANDA filings to 76 and 1 NDA (as on 31st Mar’16) 9,907 2,434 • Received 3
Slide 9: Business Highlight Q4FY16 – Other International Markets
Business Highlight Q4FY16 Other International Markets: Q4FY16 Net Sales of Rs.927 million (65.8% growth YoY) • Other International sales contributed 8.3% Other International Markets sales to total net sales for Q4FY16 INRmn • Company has presence in more than 50 3,500 international markets • Robust
Slide 10: Strategy going forward
Strategy going forward 1 India Sales: Consolidate our leadership position in the acute segment by driving growth in our mega brands 2 India Sales: Increase our market share in the chronic segment through market share acquisition and new product introductions 3 Improve our field force productivity th
Slide 11: Financials – Key P&L items (Consolidated)
Financials – Key P&L items (Consolidated) Particulars (Rs mn) Q4FY16 Q4FY15 YoY FY16 FY15 YoY growth growth Net Income from Operations 11,426 9,119 25.3% 49,915 37,434 33.3% Gross Profit 7,147 5,207 37.3% 30,304 20,528 47.6% Gross Profit margin 62.6% 57.1% 60.7% 54.8% EBITDA 1,580 1,346 17.4% 8,482
Slide 12: Financials – Key Ratios and Balance Sheet items (Consolidated)
Financials – Key Ratios and Balance Sheet items (Consolidated) Particulars FY16 FY15 RONW 19.2% 13.1% Book Value per share (Rs.) 292.9 250.8 Receivable days 41 51 Inventory days* 67 77 Payable days* 42 45 Net Working Capital days 65 83# Gross Debt (Rs. million) 6,554 13,059 Net Cash (Rs. million)**
Slide 13: Latest Shareholding Pattern
Latest Shareholding Pattern Shareholding pattern as on 31st March 2016 Non-Institution, 26.41% Promoter & Institution, Promoter Group, 6.81% 66.78% Institution – Mutual Funds, Financial Institutions, Foreign Portfolio Investors, Foreign Institutional Investors, Nationalised and Non-Nationalised Bank
Slide 14: Thank You
Thank You ALKEM